Evaluation of the effectiveness of the preoperative administration of a single-dose preparationof azithromycin, in chest surgery.

Phase 1

• Conditions: primary lung cancer

• Registration Number: JPRN-UMIN000010368
• Lead Sponsor: Surgical Oncology, Nagasaki University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2013-04-01
• Study Completion: 2016-03-31
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

Not provided

Exclusion Criteria

(1) patient with hypersensitivity to azithromycin or macrolide derivative antimicrobials (2)patinet with congenital long QT, bradycardia, arrhythmia, heart failure or electrolyte disorders such as hyperkalemia and hypomagnesemia, or patient receiving long QT-inducible drugs such as class IA or III antiarrhythmic, psychotropic and antidepressant (3)patient with severe liver dysfunction(Child Pugh C) (4)patient of aherediatry fructose intolerance symptom, glucose galactose absoroption imperfecton or sucrose isomaltase deficiency (5)patient recieving other antimicrobials (6)A pregnant woman or the patient who is nursing (7)the patient who is judged to be inappropriate by the examination medical attendant

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
perioperative infection prophylaxis in lung cancer surgery.

Secondary Outcome Measures

Name	Time	Method
concentration of azithromycin in lung, microbiological examination in lung, inflammatory cytokines expression.